Clinical trial
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and…
NCT00153101 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00153101 |
|---|---|
| Title | Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo. |
| Official title | ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Cardiovascular Diseases |
| Intervention type | Drug |
| Interventions | Telmisartan, Combination of Telmisartan and Ramipril, Ramipril |
| Enrollment | 31,546 |
| Start date | Nov 1, 2001 |
| Primary completion | Jun 1, 2008 |
| First posted | Sep 12, 2005 |
| Last update posted | May 20, 2014 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, Finland, France, Germany and 29 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: